Biomerica vs VolitionRx
BMRA and VNRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and VNRX compare
Biomerica is the larger company, worth 2.2 times as much as VolitionRx ($5.7M against $2.6M).
VolitionRx grew revenue faster over the last twelve months (86.3% versus −11.2% for Biomerica).
Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −1043% at VolitionRx.
Biomerica scores higher on the StockData Score (8 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | VNRX |
|---|---|---|
| Size and price | ||
| Market cap | $5.7M | $2.6M |
| Share price | $1.24 | $0.189 |
| Change, 1 year | −48.8% | −97.2% |
| Change, 5 years | −96.9% | −99.7% |
| Beta (5Y) | 0.93 | 2.26 |
| Employees | 17 | 75 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | 1.0× (better) |
| P/B | 1.6× | – |
| FCF yield | – | −760% |
| Fair value | $2.44 | – |
| Margin of safety | 49.4% | – |
| Growth | ||
| Revenue growth (TTM) | −11.2% | 86.3% (better) |
| Revenue growth, 5Y average | −9.2% | 164% (better) |
| Profitability | ||
| Gross margin | 0.90% | – |
| Operating margin | −125% (better) | −790% |
| Net margin | −115% (better) | −1043% |
| FCF margin | – | −797% |
| Return on equity | −114% | – |
| Return on invested capital | −284% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.91 (better) | 0.30 |
| Altman Z-score | −10.62 (better) | −53.84 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −55.7% (better) | −751% |
| Shareholder yield | −55.7% (better) | −751% |
| Ownership | ||
| Held by institutions | 2.7% | 14.1% |
| Held by insiders | 27.4% | – |
| Insider net buying, 12 months | $158K (better) | $0 |
| Short interest, % of float | 0.37% | – |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- VNRX stock overview
- VNRX income statement
- VNRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.